Last Chance Recombinant Human Activin Ria/alk-2 (c-fc) Get 30% Off Today [gYodkCn1]

High-Quality Last Chance Recombinant Human Activin Ria/alk-2 (c-fc) Get 30% Off Today [gYodkCn1]

Introducing our premium Last Chance Recombinant Human Activin Ria/alk-2 (c-fc) Get 30% Off Today [gYodkCn1], a cutting-edge research tool designed for advanced molecular biology applications. This recombinant protein, expressed in HEK293 cells, offers researchers a reliable source for studying the TGF-beta superfamily ligands and their interactions with the Activin RIA receptor. Its high purity, >95%, ensures accurate and reproducible results in your experiments.

Product Specifications and Properties

Our Last Chance Recombinant Human Activin Ria/alk-2 (c-fc) Get 30% Off Today [gYodkCn1] is a glycosylated 65 kDa type I receptor, with a calculated molecular weight of 38.2 kDa and an observed molecular weight of 38-45 kDa. It is tagged with C-Fc for easy detection and purification. This protein is produced in a controlled environment, ensuring minimal endotoxin levels (<1.0 EU per μg) and providing a stable, reliable research tool. Key features include:

• Expressed in HEK293 cells for consistent quality and purity
• High purity (>95%) for accurate and reproducible results
• Tagged with C-Fc for easy detection and purification

Applications and Benefits

The Last Chance Recombinant Human Activin Ria/alk-2 (c-fc) Get 30% Off Today [gYodkCn1] is a versatile research tool with a wide range of applications. It is ideal for studying the role of TGF-beta superfamily ligands in various biological processes, such as gastrulation, skeletal system development, and cardiac morphogenesis. This protein can be used to investigate the interaction between Activin RIA and RGM-B/DRAGON, a BMP coreceptor, as well as its phosphorylation of the coreceptor Endoglin. By using this product, researchers can:

• Gain insights into the complex signaling pathways involving TGF-beta superfamily ligands
• Explore the role of Activin RIA in various biological processes and diseases
• Develop novel therapeutic strategies for conditions involving TGF-beta signaling